Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti–RNA binding protein autoantibodies

Authors

  • Jing Hua,

    1. Mary Kirkland Center for Lupus Research and Department of Medicine, Hospital for Special Surgery, and Weill Medical College of Cornell University, New York, New York
    Search for more papers by this author
    • Drs. Hua, Kirou, and Crow have applied for a patent for an assay to measure type I interferon functional activity. Dr. Crow is a member of the Scientific Advisory Board of XDx, Inc., for which she receives no compensation, and owns stock in XDx, Inc.

  • Kyriakos Kirou,

    1. Mary Kirkland Center for Lupus Research and Department of Medicine, Hospital for Special Surgery, and Weill Medical College of Cornell University, New York, New York
    Search for more papers by this author
    • Drs. Hua, Kirou, and Crow have applied for a patent for an assay to measure type I interferon functional activity. Dr. Crow is a member of the Scientific Advisory Board of XDx, Inc., for which she receives no compensation, and owns stock in XDx, Inc.

  • Christina Lee,

    1. Mary Kirkland Center for Lupus Research and Department of Medicine, Hospital for Special Surgery, and Weill Medical College of Cornell University, New York, New York
    Search for more papers by this author
  • Mary K. Crow

    Corresponding author
    1. Mary Kirkland Center for Lupus Research and Department of Medicine, Hospital for Special Surgery, and Weill Medical College of Cornell University, New York, New York
    • Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021
    Search for more papers by this author
    • Drs. Hua, Kirou, and Crow have applied for a patent for an assay to measure type I interferon functional activity. Dr. Crow is a member of the Scientific Advisory Board of XDx, Inc., for which she receives no compensation, and owns stock in XDx, Inc.


Abstract

Objective

Peripheral blood mononuclear cells (PBMCs) from patients with systemic lupus erythematosus (SLE) have increased expression of genes typically induced by type I interferon (IFN). However, it has been difficult to identify and quantify the factors responsible for activation of the IFN pathway in SLE. To characterize these mediators, we developed an assay that measures the functional effects of plasma or serum components on the gene expression of cultured target cells.

Methods

WISH epithelial cell line cells were cultured with medium, with recombinant IFNα, IFNβ, or IFNγ, or with 50% plasma from SLE patients (n = 73), rheumatoid arthritis (RA) patients (n = 19), or healthy donors (n = 30). Real-time quantitative polymerase chain reaction was used to determine WISH cell expression of IFN target genes, including PRKR, IFIT1, IFI44, MX1, and C1orf29 (preferentially induced by IFNα) and CXCL9 (Mig) (preferentially induced by IFNγ).

Results

IFNα-regulated genes were induced by SLE plasma samples, but not by most of the RA or healthy control plasma samples. The activity in SLE plasma was inhibited >90% by anti-IFNα antibody, but not by anti-IFNβ or anti-IFNγ antibodies. The expression of each IFNα target gene induced by SLE plasma correlated with the expression of that gene studied ex vivo in PBMCs from the same patients and with the titer of anti–RNA binding protein (anti-RBP)–specific autoantibodies. Plasma activity paralleled PBMC expression of IFNα-inducible genes over time.

Conclusion

IFNα in SLE plasma is a major stimulus of IFN target gene expression and is related to expression of those genes in PBMCs from SLE patients and to the titer of anti-RBP autoantibodies. These data provide additional support for the view that IFNα mediates immune system activation and dysregulation in SLE.

Ancillary